Pazopanib is an antineoplastic agent used in the treatment of advanced renal cell cancer and advanced soft tissue sarcoma in patients with prior chemotherapy. Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity.
- Mechanism
- Curator reviewed
Pazopanib is a second-generation multitargeted tyrosine kinase inhibitor against vascular endothelial growth factor receptor-1, -2, and -3, platelet-derived growth factor receptor-alpha, platelet-derived growth factor receptor-beta, and c-kit. These receptor targets are part of the angiogenesis pathway that facilitates the formation of tumour blood vessel for tumour survival and growth.
- Primary indication
- Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)Curator reviewed · 3 structured indications
- Formula / weight
- C21H23N7O2S · 437.518 g/mol (avg)
- First approval
- Canada, 2015 · United States, 2009 · European Union, 2016
- Code names
- GW 78603 · GW-786034
- Brand names
Resolves to
CUIHSIWYWATEQL-UHFFFAOYSA-NSMILESCN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1What you can answer from here — as of September 23, 2026
Which drugs share a target with Pazopanib, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account